Array BioPharma Inc. Securities Litigation (2019)

If you purchased a significant amount of shares of Array BioPharma Inc. (NASDAQ: ARRY), you have certain options. Investors should register for updates.

 

Lawsuit Overview

Defendant:Array BioPharma Inc.
Date Filed:July 1st, 2019
Sector:Health Care
Industry:Major Pharmaceuticals

According to the Complaint, Array BioPharma Inc. is a fully integrated biopharmaceutical company focused on the discovery, development, and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases.

This action stems from a proposed transaction announced on June 17, 2019, pursuant to which Array BioPharma Inc. will be acquired by Pfizer Inc.

On June 14, 2019, Array's Board of Directors caused the Company to enter into an agreement and plan of merger with Pfizer.

On June 28, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction.

The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed
Transaction, which renders the Solicitation Statement false and misleading.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Array BioPharma Inc.

 
First Identified Complaint

Michael Kent, et al. v. Array BioPharma Inc., et al.

Date Filed:July 1st, 2019
Class Period Start:June 17th, 2019
Class Period End:July 1st, 2019
First Identified Complaint Filings
#Document TitleFiling Date